ArticleAdvances in orthopedics2025
Impact of Intravenous Tranexamic Acid at Hospital Admission on Blood Transfusion Rates in Geriatric Extracapsular Hip Fracture Patients.
Article in Advances in orthopedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Intravenous Tranexamic Acid at Hospital Admission on Blood Transfusion Rates in Geriatric Extracapsular Hip Fracture Patients.Advances in orthopedics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Geriatric hip fractures often require allogenic blood transfusions, which increases the risk of transfusion related complications. Tranexamic acid (TXA) has been shown to have a positive effect on hip fractures, with the American Academy of Orthopedic Surgeons (AAOS) recommending its use; however, optimal dosing and timing has not been delineated in the literature. This study evaluates the effectiveness of early TXA administration in reducing transfusion rates in extracapsular geriatric hip fracture patients. Methods: From 2021 to 2023, a retrospective chart review compared geriatric fragility hip fracture (AO/OTA 31A) patients who received TXA at admission (1-g IV at presentation and 1-g IV three hours later) with those who did not. The primary outcome evaluated was allogenic blood transfusion rates. Patient demographics, hemoglobin levels during admission, hidden blood loss, length of hospital stay, and 90-day perioperative complications were also recorded. Results: Among 168 patients, 102 received TXA and 66 did not. There was no statistically significant difference in allogenic transfusion rates between the groups ( Conclusion: Our findings align with recent literature that questions TXA's effectiveness in reducing transfusion rates in this population. Early TXA administration may not adequately address hidden blood loss in geriatric hip fractures, possibly due to high comorbidity burden, pre-existing anemia, and delayed surgery. Further research is necessary to explore alternative strategies for managing early blood loss and optimizing outcomes in this population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.